Avonex Share of First-Line Therapy Among Multiple Sclerosis Patients has ... MarketWatch (press release) Patient profiles for the eight DMAs in late clinical development (Aubagio, BG-12, alemtuzumab, PEG-Avonex, Copaxone 40mg 3x weekly, daclizumab, laquinimod, ocrelizumab) are also characterized. About BioTrends Research Group. BioTrends Research ... |
